关于公司
- 法定名称: Fermion Oy
- 注册国家: Finland
- 地址: Koivu-Mankkaan tie 6 A, FI-02200 Espoo
- 员工人数: 250 - 499
描述:
Fermion, a wholly owned subsidiary of Orion Corporation and headquartered in Espoo, Finland, is a fully integrated CDMO offering API and formulation services. Its API portfolio includes over 30 generic APIs and more than 10 NCEs, with two manufacturing sites and R&D facilities in Finland. Fermion has expanded capabilities in HPAPI production. Drug product CMO services cover hormonal and non-hormonal semi-solids, cytotoxic oral solids, and packaging, supported by three manufacturing sites and one packaging center under Orion. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
业务活动
合同与外包服务
制造商服务提供商合同制造商(CMO)原料药生产商
原研原料药
制造商合同制造商(CMO)原料药生产商
法规事务与市场情报服务
服务提供商
实验室与分析服务
服务提供商
我们的产品与服务
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Certifications
FDA
DMF
GMP
Proofs
CPHI Americas 2026
06/2026 – 06/2026
CPHI Americas 2026
评分
(0)
(0)
(0)
(0)
(0)
评论
筛选：
排序方式：
暂无评论。
留下您的评分和评论